Jodi Holloway
Nurse Practitioner · Newton, IANPI 1013163427
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $12.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$634
- AbbVie$348
- Boehringer Ingelheim$228
- Novo Nordisk$202
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$179
- Lilly USA, LLC$144
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,818100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 96 | $634 |
| AbbVie | 20 | $348 |
| Boehringer Ingelheim | 12 | $228 |
| Novo Nordisk | 10 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $179 |
| Lilly USA, LLC | 9 | $144 |
| Bayer | 7 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $114 |
| Astellas Pharma US Inc | 7 | $109 |
| AstraZeneca | 7 | $106 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $97 |
| GSK | 6 | $94 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Amgen | 3 | $52 |
| Sanofi Pasteur Inc. | 2 | $47 |
| Exact Sciences | 1 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Insulet Corporation | 1 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| SPR Therapeutics, Inc | 1 | $24 |
| Johnson & Johnson | 1 | $18 |
| Abbott | 1 | $16 |
| Dynavax Technologies Corporation | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Radius Health, Inc. | 1 | $14 |
| Coopersurgical, Inc. | 1 | $14 |
| Novartis | 1 | $11 |
| Genentech USA, Inc. | 1 | $5 |
How this compares
$2,818 in reported general payments places this provider in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $113,304 |
| OzempicSemaglutide | 60 | $71,380 |
| JardianceEmpagliflozin | 74 | $68,720 |
| EliquisApixaban | 54 | $47,003 |
| RybelsusSemaglutide | 40 | $44,067 |
| MounjaroTirzepatide | 21 | $22,295 |
| TrulicityDulaglutide | 13 | $21,531 |
| JanuviaSitagliptin Phosphate | 29 | $21,503 |
| MyrbetriqMirabegron | 22 | $20,845 |
| XareltoRivaroxaban | 13 | $20,448 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $14,286 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $10,854 |
| FarxigaDapagliflozin Propanediol | 14 | $10,219 |
| GemtesaVibegron | 11 | $5,095 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $94 | $131,768145 claims |
| Novo NordiskOzempic, Rybelsus | $202 | $115,447100 claims |
| Boehringer IngelheimJardiance | $228 | $68,72074 claims |
| PfizerEliquis | $634 | $47,00354 claims |
| Lilly USA, LLCMounjaro, Trulicity | $144 | $43,82734 claims |
| Astellas Pharma US IncMyrbetriq | $109 | $20,84522 claims |
| Johnson & JohnsonXarelto | $18 | $20,44813 claims |
| AstraZenecaFarxiga, Symbicort | $106 | $15,02631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,346 nurse practitioner providers in Iowa.
Other nurse practitioner in Newton
- Nicole MorganDes Moines$106K
- Julie CoffeyIowa City$31K
- Mary JohnsonDavenport$30K
- Megan Hart FernandezCedar Rapids$19K
- Carla HuberCedar Rapids$18K
- Beth ChiaWest Des Moines$15K
- Margaret KinneyRed Oak$13K
- Abbey ModlinDes Moines$12K
- Jonathon HenningsWaterloo$11K
- Michaela JohnsonWaterloo$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.